Cannabis Research - Efficacy
Chronic Cannabis Use in the Compassionate Investigational New Drug Program
An Examination of the Benefits and Adverse Effects of Legal Clinical Cannabis
Ethan Russo, Mary Lynn Mathre, Al Byrne, Rob Velin, Paul Bach, Juan Sanchez-Ramos, Kristin Kirlin
Presentation by Ethan Russo
ABSTRACT. The Missoula Chronic Clinical Cannabis Use Study was
proposed to investigate the therapeutic bepnefits and adverse effects of
prolonged use of "medical marijuana" in a cohort of seriously ill patients.
Use of cannabis was approved through the Compassionate Investigational
New Drug (IND) program of the Food and Drug Administration
(FDA). Cannabis is obtained from the National Institute on Drug
Abuse (NIDA), and is utilized under the supervision of a study physician.
The aim of this study is to examine the overall health status of 4 of
the 7 surviving patients in the program. This project provides the first opportunity
to scrutinize the long-term effects of cannabis on patients who
have used a known dosage of a standardized, heat-sterilized quality-controlled
supply of low-grade marijuana for 11 to 27 years.
Results demonstrate clinical effectiveness in these patients in treating
glaucoma, chronic musculoskeletal pain, spasm and nausea, and spasticity
of multiple sclerosis. All 4 patients are stable with respect to their
chronic conditions, and are taking many fewer standard pharmaceuticals
Mild changes in pulmonary function were observed in 2 patients,
while no functionally significant attributable sequelae were noted in any
other physiological system examined in the study, which included: MRI
scans of the brain, pulmonary function tests, chest X-ray, neuropsychological
tests, hormone and immunological assays, electroencephalography,
P300 testing, history, and neurological clinical examination.
These results would support the provision of clinical cannabis to a
greater number of patients in need. We believe that cannabis can be a
safe and effective medicine with various suggested improvements in the
existing Compassionate IND program.
CANNABINOIDS: POTENTIAL ANTICANCER AGENTS
Cannabinoids - the active components of Cannabis sativa and their derivatives - exert
palliative effects in cancer patients by preventing nausea, vomiting and pain and by stimulating
appetite. In addition, these compounds have been shown to inhibit the growth of tumour cells in
culture and animal models by modulating key cell-signalling pathways. Cannabinoids are usually
well tolerated, and do not produce the generalized toxic effects of conventional chemotherapies.
So, could cannabinoids be used to develop new anticancer therapies?
- Studies Showing Anti-Cancer Effect
A bibliography of 22 studies which document the anti-cancer/tumor properties of the cannabinoids.
- The Society for Neuroscience: Marijuana-Like Compounds May Aid Array Of Debiliatiing Conditions Ranging From Parkinson's Disease To Pain
- No longer a pipe dream, new animal research now indicates that marijuana-like compounds can aid a bevy of debilitating conditions, ranging from brain disorders such as amyotrophic lateral sclerosis (ALS) and Parkinson's disease, to pain and obesity.
- Further Reading